COSCIENS Biopharma Inc
CSCI3.880USD
+0.060+1.57%
取引時間 （ET）15分遅れの株価
12.21M時価総額
損失額直近12ヶ月PER
詳細情報 COSCIENS Biopharma Inc 企業名
COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources used in cosmeceutical products (i.e., oat beta glucan and avenanthramides, which are found in skincare product brands like Aveeno and Burt’s Bees formulations) and being developed as potential nutraceuticals and/or pharmaceuticals.
企業情報
企業コードCSCI
会社名COSCIENS Biopharma Inc
上場日Dec 19, 1995
最高経営責任者「CEO」Ms. Anna Biehn
従業員数- -
証券種類Ordinary Share
決算期末Dec 19
本社所在地C/O Norton Rose Fulbright Canada Llp
都市TORONTO
証券取引所The Toronto Stock Exchange
国Canada
郵便番号M5K 1E7
電話番号18439003201
ウェブサイトhttps://www.cosciensbio.com/
企業コードCSCI
上場日Dec 19, 1995
最高経営責任者「CEO」Ms. Anna Biehn
役員一覧
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Gilles R. Gagnon
Mr. Gilles R. Gagnon
Director
Director
41.96K
--
Dr. Ulrich Kosciessa
Dr. Ulrich Kosciessa
Director
Director
1.85K
--
Ms. Nicola Ammer
Ms. Nicola Ammer
Senior Vice President - Clinical Development, Chief Medical Officer
Senior Vice President - Clinical Development, Chief Medical Officer
--
--
Mr. Pierre Labbe, CPA
Mr. Pierre Labbe, CPA
Director
Director
--
--
Dr. Matthias Gerlach
Dr. Matthias Gerlach
Senior Vice President - Manufacturing and Supply Chain, Managing Director - AEZS Germany
Senior Vice President - Manufacturing and Supply Chain, Managing Director - AEZS Germany
--
--
Mr. Giuliano La Fratta
Mr. Giuliano La Fratta
Chief Financial Officer, Senior Vice President, Director
Chief Financial Officer, Senior Vice President, Director
--
--
Ms. Genevieve Foster
Ms. Genevieve Foster
Director
Director
--
--
Dr. William W. Li, M.D.
Dr. William W. Li, M.D.
Director
Director
--
--
Mr. Michel Regnier
Mr. Michel Regnier
Senior Vice President, Chief Technology Officer
Senior Vice President, Chief Technology Officer
--
--
Mr. Ronald W. (Ronnie) Miller
Mr. Ronald W. (Ronnie) Miller
Chairman of the Board
Chairman of the Board
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Gilles R. Gagnon
Mr. Gilles R. Gagnon
Director
Director
41.96K
--
Dr. Ulrich Kosciessa
Dr. Ulrich Kosciessa
Director
Director
1.85K
--
Ms. Nicola Ammer
Ms. Nicola Ammer
Senior Vice President - Clinical Development, Chief Medical Officer
Senior Vice President - Clinical Development, Chief Medical Officer
--
--
Mr. Pierre Labbe, CPA
Mr. Pierre Labbe, CPA
Director
Director
--
--
Dr. Matthias Gerlach
Dr. Matthias Gerlach
Senior Vice President - Manufacturing and Supply Chain, Managing Director - AEZS Germany
Senior Vice President - Manufacturing and Supply Chain, Managing Director - AEZS Germany
--
--
Mr. Giuliano La Fratta
Mr. Giuliano La Fratta
Chief Financial Officer, Senior Vice President, Director
Chief Financial Officer, Senior Vice President, Director
--
--
収益内訳
通貨: USD更新時刻: Sun, Apr 6
通貨: USD更新時刻: Sun, Apr 6
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
データなし
地域別USD
会社名
収益
比率
Switzerland
4.32M
95.98%
Ireland
122.00K
2.71%
Other
48.00K
1.07%
Denmark
11.00K
0.24%
事業別
地域別
データなし
株主
更新時刻: Fri, Aug 1
更新時刻: Fri, Aug 1
株主統計
種類
株主統計
株主統計
比率
Goodwood Inc.
8.18%
Gagnon (Gilles R)
1.33%
Susquehanna International Group, LLP
0.38%
RBC Dominion Securities, Inc.
0.12%
TD Waterhouse Canada, Inc.
0.12%
Other
89.87%
株主統計
株主統計
比率
Goodwood Inc.
8.18%
Gagnon (Gilles R)
1.33%
Susquehanna International Group, LLP
0.38%
RBC Dominion Securities, Inc.
0.12%
TD Waterhouse Canada, Inc.
0.12%
Other
89.87%
種類
株主統計
比率
Investment Advisor/Hedge Fund
8.19%
Individual Investor
1.49%
Investment Advisor
0.70%
Research Firm
0.11%
Bank and Trust
0.04%
Other
89.47%
機関投資家保有株
更新時刻: Tue, Jul 1
更新時刻: Tue, Jul 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q2
37
331.27K
10.53%
-6.89K
2025Q1
40
333.44K
10.61%
+29.17K
2024Q4
39
327.35K
8.67%
+13.77K
2024Q3
37
287.99K
7.73%
+16.16K
2024Q2
43
256.95K
8.09%
+189.65K
2024Q1
39
61.15K
4.98%
+40.02K
2023Q4
42
13.03K
1.07%
-9.47K
2023Q3
49
18.14K
1.49%
-6.74K
2023Q2
52
14.44K
1.19%
-13.85K
2023Q1
54
14.56K
1.20%
-15.46K
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
Goodwood Inc.
257.26K
8.18%
--
--
Jun 03, 2025
Gagnon (Gilles R)
41.96K
1.33%
--
--
Mar 26, 2025
Susquehanna International Group, LLP
11.91K
0.38%
+11.91K
--
Mar 31, 2025
RBC Dominion Securities, Inc.
3.87K
0.12%
-69.00
-1.75%
Mar 31, 2025
TD Waterhouse Canada, Inc.
3.72K
0.12%
--
--
Mar 31, 2025
Desjardins Securities Inc.
2.81K
0.09%
-1.06K
-27.39%
Mar 31, 2025
Li (William W. M.D.)
2.40K
0.08%
--
--
Mar 26, 2025
UBS Financial Services, Inc.
2.34K
0.07%
+1.65K
+240.67%
Mar 31, 2025
Kosciessa (Ulrich)
1.85K
0.06%
--
--
Jun 03, 2025
National Bank of Canada
1.12K
0.04%
-4.80K
-81.05%
Mar 31, 2025
詳細を見る
関連ETF
銘柄名
比率
データなし
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
種類
比率
May 01, 2024
Merger
4<1
May 01, 2024
Merger
4<1
May 01, 2024
Merger
4<1
May 01, 2024
Merger
4<1
Jul 19, 2022
Merger
25<1
Jul 19, 2022
Merger
25<1
日付
種類
比率
May 01, 2024
Merger
4<1
May 01, 2024
Merger
4<1
May 01, 2024
Merger
4<1
May 01, 2024
Merger
4<1
Jul 19, 2022
Merger
25<1
Jul 19, 2022
Merger
25<1
Jul 19, 2022
Merger
25<1
Jul 19, 2022
Merger
25<1
